Delving into the Latest Updates on Deoxyspergualin hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-Gusperimus, 15-Deoxyspergualin, 15-Desoxyspergualin

+ [20]

Target

Cytokines

Mechanism

Cytokines inhibitors

Therapeutic Areas

Immune System Diseases

Active Indication

Renal transplant rejectionAutoimmune DiseasesGraft Rejection

Inactive Indication

Granulomatosis With PolyangiitisHypersensitivityLupus Nephritis+ [5]

Originator Organization

Nippon Kayaku Co., Ltd.

Active Organization

Nippon Kayaku Co., Ltd.Institute of Immunology

Inactive Organization

Nordic Ltd.

Drug Highest PhaseApproved

First Approval Date

JP (19 Jan 1994),

Renal transplant rejection

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC17H37N7O3

InChIKeyIDINUJSAMVOPCM-INIZCTEOSA-N

CAS Registry89149-10-0

View All Structures (2)

Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)

The aim of the study is to assess the efficacy (superiority testing) of gusperimus compared to conventional treatment in patients with a relapse of Wegener Granulomatosis with or without ongoing steroids, and/or immunosuppressive therapy. Further, to evaluate the safety and quality of life of gusperimus treatment compared to standard treatment in patients with relapse of Wegener Granulomatosis receiving glucocorticoids.

Start Date01 Nov 2011

Sponsor / Collaborator

Nordic Pharma SAS

EUCTR2011-001219-30-SE / Not yet recruitingNot Applicable

Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus versus Conventional Therapy in Relapse of Granulomatosis with Polyangiitis (Wegener’s Granulomatosis) - SPARROW study – SPAnidin in Relapsing gRanulomatosis with pOlyangiitis (Wegener’s granulomatosis)

Start Date31 Aug 2011

Sponsor / Collaborator

Nordic Pharma Group

100 Clinical Results associated with Deoxyspergualin hydrochloride

Login to view more data

100 Translational Medicine associated with Deoxyspergualin hydrochloride

Login to view more data

100 Patents (Medical) associated with Deoxyspergualin hydrochloride

Login to view more data

884

Literatures (Medical) associated with Deoxyspergualin hydrochloride

01 Jan 2025·Bioresource Technology

Upcycling of melanoidin-rich Chinese distilled spent grain through solid-state fermentation by Aspergillus awamori

Article

Author: Casertano, Melania ; Arslan-Tontul, Sultan ; Yang, Shiqi ; Vilas-Franquesa, Arnau ; Nie, Yao ; Xu, Yan ; Fogliano, Vincenzo ; Fan, Wenlai

This study investigated the upcycling of distilled spent grain (DSG), a melanoidin-rich by-product of the Chinese liquor industry, via fungal solid-state fermentation (SSF). Two fungi, Aspergillus oryzae and Aspergillus awamori, were tested, with A. awamori growing better on DSG than A. oryzae. SSF with A. awamori increased the concentration of water-soluble protein and phenolic compounds in DSG extracts by 46.5 % and 52.5 %, respectively, and reduced melanoidin level by 73.5 % w/w of DSG, suggesting A. awamori could metabolize melanoidins. Submerged fermentation (SmF) using isolated DSG melanoidins as sole carbon and nitrogen sources confirmed this observation. After 3 days of fermentation, A. awamori and A. oryzae biomass reached 2.5 g/L and 1.5 g/L, quenching melanoidin color by 24.4 % and 12.4 %, respectively. SmF by A. awamori also released free arabinose, glucose, and xylose. Data highlighted the possibility of converting melanoidins into edible mycelia resources, potentially applicable to various melanoidin-rich food by-products.

01 May 2024·International Journal of Biological Macromolecules

Tunable durian seed gum-derived eutectogel as a novel coating material: Rheological, thermal, textural and barrier properties for enhanced food preservation

Article

Author: Koh, Qi Qi ; Chew, Zhi Ling ; Kua, Yin Leng ; Tan, Khang Wei ; Gan, Suyin ; Lee, Terri Zhuan Ean ; Chu, Eng Eng

As a promising green and sustainable coating material, gum was extracted from durian seed to produce eutectogel, which the properties were tunable using natural deep eutectic solvent (NADES). Ten different eutectogels were successfully synthesized using durian seed gum (DSG) and xanthan gum (XG) gelators at different composition (5, 10, 15 %) to gel choline chloride-glucose (1:1), choline chloride-fructose (1:2) and betaine-glucose-water (1:1:1) NADESs. Results revealed that eutectogel was non-Newtonian and weak gel material with excellent thermostability up to 200 °C. When the gum content increased, the resulted eutectogel showed higher viscosity, yield stress, hardness, gumminess, adhesiveness, and weight holding capacity. In overall, choline chloride-fructose (1:2) NADES and 10 % of DSG formed an excellent eutectogel which remained stable and compatible upon 12 weeks of storage. It displayed superior viscoelastic, texture, gases and moisture barrier properties which were beneficial for food coating application. This eutectogel was able to extend the shelf life of fresh-cut apples during storage with lower weight loss and higher total phenolic content (TPC). The potential future of this well-characterized tunable DSG-derived eutectogel includes, but not limited to, food and pharmaceutical industries, smart sensing, flexible wearable electronics, water purification, supercapacitors and batteries.

01 Dec 2023·Journal of Cutaneous Pathology

Correlation of desmoglein 1 and 3 immunohistochemistry with autoantibody levels and clinical severity in pemphigus

Article

Author: Pradeep, Aiswarya ; Eapen, Malini ; Kani, Keerthiga ; Jagadeeshan, Soumya

AbstractBackgroundPemphigus is a chronic potentially fatal autoimmune bullous disorder. Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are the two common subtypes. PV is the most common and aggressive type characterized by oral mucosal erosions and cutaneous lesions. PF presents with blisters on the scalp, face, and upper trunk, and spares the mucosae. Direct immunofluorescence (DIF) is the gold standard for diagnosis. Immunohistochemistry (IHC) is an emerging alternate diagnostic tool. In this study, our objectives were to identify the staining patterns of desmoglein 1 (dsg 1) and desmoglein 3 (dsg 3) IHC and to correlate the same with autoantibody levels and clinical severity in patients with PV and PF.MethodsForty‐nine clinically, histologically, and DIF‐confirmed cases of pemphigus were included in the study. The IHC patterns were scored from 0 to 3+ with 3+ dsg 1 IHC exhibiting intense membranous staining in the upper layers of the epidermis and 3+ dsg 3 IHC showing intense basal layer staining. Enzyme‐linked immunosorbent assay (ELISA) for anti‐dsg 1 and 3 antibodies was performed in 38 cases where serum samples were available. The pemphigus disease activity index system was utilized for clinical scoring.ResultsA 0 to 1+ score was observed for dsg 1 IHC in 100% of PF cases. A score of 0 to 1+ was observed for dsg 3 IHC in 97.3% of PV cases. One hundred percent of cases with PF and 83.9% of patients with PV tested positive for ELISA anti‐dsg 1 and 3 antibody titers, respectively. Anti‐dsg 1 and 3 ELISA titers significantly correlated with the dsg 1 and dsg 3 IHC scores. The mucosal scores showed a significant association with both dsg 1 and 3 IHC (p < 0.001). The cutaneous scores showed a significant association with the dsg 3 IHC (p < 0.001).ConclusionThe IHC patterns for dsg 1 and 3 proved reliable in giving concordant results with the ELISA antibody titers and clinical severity.

100 Deals associated with Deoxyspergualin hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Deoxyspergualin hydrochloride	L04AA19	DB12991

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Renal transplant rejection	JP	Nippon Kayaku Co., Ltd.	19 Jan 1994

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Granulomatosis With Polyangiitis	Phase 2	ES	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Phase 2	GB	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Phase 2	SE	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Phase 2	DE	Nordic Ltd.	-
Multiple Sclerosis	Phase 2	FR	Nippon Kayaku Co., Ltd.	-
Multiple Sclerosis	Phase 2	DE	Nippon Kayaku Co., Ltd.	-
Granulomatosis With Polyangiitis	Discovery	ES	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Discovery	GB	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Discovery	DE	Nordic Ltd.	-
Granulomatosis With Polyangiitis	Discovery	SE	Nordic Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00709722 (Pubmed \| J Rheumatol)	Phase 1/2	Lupus Nephritis	21	15-deoxyspergualin	(lqartbkinc) = Five patients dropped out due to adverse events or serious adverse events including fever, leukopenia, oral candidiasis, herpes zoster or pneumonia jebjobbuak (jybzgtkkym ) View more	-	01 Mar 2011